Generic Line
AAM: Patients Nearly 3 Times More Likely to Not Pick Up Branded Drugs
Patients are 266 percent more likely to not pick up brand-name medications after requesting them at a pharmacy, compared to generic prescriptions, according to the Association for Accessible Medicine’s annual report. Source: Generic Line
Read MoreFDA Rejects Coherus’ Neulasta Biosimilar, Calls for New Analyses
The FDA rejected Coherus Bioscience’s proposed biosimilar for Amgen’s Neulasta, Coherus announced. Source: Generic Line
Read MoreJury Awards GSK $235M After Teva Adds CHF Indication to Coreg Label
A federal jury awarded GlaxoSmithKline $235 million in a suit against Teva, saying the generics manufacturer infringed on GSK’s patent for the cardiovascular drug Coreg when Teva marketed its generic for chronic heart failure as well as high blood pressure. Source: Generic Line
Read MoreWHO Essential Medicines List Adds Drugs for Hep C, HIV & New Antibiotics
The World Health Organization published its biennial update to its list of essential medicines, adding therapies for hepatitis C, HIV and leukemia, as well as new advice on combating antimicrobial drug resistance. Source: Generic Line
Read MorePTAB Nixes Two More Humira Dosing Patents Following Coherus’ Challenges
The PTO invalidated two more AbbVie patents on dosing regimens for Humira after continuing challenges from Coherus, which plans to submit its biosimilar version of the blockbuster drug for FDA approval later this year. Source: Generic Line
Read MoreCBO Scores User Fee Reauthorization Package
The Congressional Budget Office officially scored the Senate bill reauthorizing the FDA’s user fee agreements, saying it would add $740 million to the budget and a negligible amount to the deficit over its five-year life. Source: Generic Line
Read MoreQuintilesIMS Report: Drug Spending Growth Slows to 5.8% in 2016
Spending on medicines topped $450 billion in 2016, rising less than half as fast as the industry has seen over the past two years. Source: Generic Line
Read MoreAstellas Sues Roxane over Generic Copy of Billion-Dollar Drug Xtandi
Astellas Pharma filed suit against generics makers Roxane Laboratories, West-Ward Pharmaceuticals and Hikma Pharmaceuticals over their copycat version of Xtandi. Source: Generic Line
Read MoreMembers of Congress Urge CMS to Set New Billing Codes for Biosimilars
Fifty-two representatives and nine senators sent letters to HHS Secretary Tom Price and CMS Administrator Seema Verma, urging them to reverse current Medicare policy for the reimbursement for biosimilar products. Source: Generic Line
Read MoreFDA Approves First Strattera Generic, Plus Six Other First-Time Approvals
The FDA approved the first generic versions of Strattera (atomoxetine) to treat attention-deficit hyperactivity disorder in pediatric and adult patients, including multiple strengths manufactured by Apotex, Teva, Aurobindo Pharma and Glenmark Pharmaceuticals. Source: Generic Line
Read More